Herbert J. Conrad - 01 Nov 2023 Form 4 Insider Report for Matinas BioPharma Holdings, Inc. (MTNB)

Reporting relationship: Director
Issuer ticker: MTNB
Reported as of: 01 Nov 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Nov 2023, 16:49:48 UTC
Prior SEC filing: 20 Jun 2023
Next SEC filing: 17 Jun 2024
Source filing: View source filing
Reporting owner signature: /s/ Keith A. Kucinski, attorney-in fact for Herbert J. Conrad

Key filing fact

Herbert J. Conrad filed Form 4 for Matinas BioPharma Holdings, Inc. (MTNB) on 03 Nov 2023.

Key facts

This page summarizes Herbert J. Conrad's Form 4 filing for Matinas BioPharma Holdings, Inc. (MTNB).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 03 Nov 2023, 16:49.

Change

Previous filing in this sequence was filed on 20 Jun 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MTNB transaction Derivative

Stock option (right to buy)

Award

Transaction value: $0
Shares: +437,244
Change %
Price: $0.000000
Shares after: 437,244
Date: 01 Nov 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 437,244
Exercise price: $0.2088
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on November 1, 2023. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan.